Se ha realizado un estudio experimental sobre el tumor IL-7, implantado subcutáneamente en ratas Wistar, al objeto de verificar si la administración sistémica o intralesional de dexametasona puede ejercer un efecto antitumoral. Los resultados obtenidos muestran que, tras cuatro semanas de tratamiento, la administración de este fármaco, ya sea por vía sistémica o mediante inyección directa intratumoral, no modifica significativamente el volumen del tumor ni el índice de proliferación celular. Teniendo en cuenta el carácter neuroectodérmico primitivo del tumor IL-7, los presentes resultados sugieren la ineficacia de la dexametasona, como agente citolítico, sobre neoplasias cerebrales humanas que muestren características histológicas de tumor neuroectodérmico primitivo.
An experimental study has been performed on the IL-7 tumor growing in the subcutaneous tissue of Wistar rats. The possibility of an antitumor effect of dexamethasone, after systemic or intralesional administration was evaluated. After four weeks of dexamethasone administration, a reduction in the tumor volume or proliferation cell index was not reached. Due to the fact that IL-7 may be considered as a primitive neuroectodermal tumor, our present results suggest that dexamethasone is inefficacious as a cytolytic agent for the control of human primitive neuroectodermal tumors.
Article
If it is the first time you have accessed you can obtain your credentials by contacting Elsevier Spain in suscripciones@elsevier.com or by calling our Customer Service at902 88 87 40 if you are calling from Spain or at +34 932 418 800 (from 9 to 18h., GMT + 1) if you are calling outside of Spain.
If you already have your login data, please click here . p>
If you have forgotten your password you can you can recover it by clicking here and selecting the option ¿I have forgotten my password¿.